An analysis by Pharmarack, a market research firm, showed that 226 vildagliptin (anti-diabetic) brands are now available in ...

Type 2 diabetes is a global health challenge affecting more than 400 million adults. While it is often seen as a lifelong ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

Dapagliflozin propanediol is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. By reducing glucose reabsorption in the ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.

Kolkata: The prices of 53 medicines, including a large number of formulations used to treat diabetes, have been revised ...

Rajeev Juneja, vice chairman and managing director of Mumbai, Indian-based drugmaker Mankind Pharma (NSE: MANKIND), today ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

Empagliflozin is a SGLT-2 inhibitor and it has shown to significantly reduce the progression of kidney disease and heart failure.

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...